EGAGenomicsOtherCOVID-192019 novel coronavirus infectionSARS-CoV-22019-nCoV infectionsevere acute respiratory syndrome coronavirus 2coronavirus disease 2019SARS-coronavirus 2https://ega-archive.org/studies/EGAS00001004772EGAEGA study EGAS00001004772Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19EGArestrictedIn coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19.Trump Saskia S, Lukassen Soeren S, Anker Markus S MS, Chua Robert Lorenz RL, Liebig Johannes J, Thürmann Loreen L, Corman Victor Max VM, Binder Marco M, Loske Jennifer J, Klasa Christina C, Krieger Teresa T, Hennig Bianca P BP, Messingschlager Marey M, Pott Fabian F, Kazmierski Julia J, Twardziok Sven S, Albrecht Jan Philipp JP, Eils Jürgen J, Hadzibegovic Sara S, Lena Alessia A, Heidecker Bettina B, Bürgel Thore T, Steinfeldt Jakob J, Goffinet Christine C, Kurth Florian F, Witzenrath Martin M, Völker Maria Theresa MT, Müller Sarah Dorothea SD, Liebert Uwe Gerd UG, Ishaque Naveed N, Kaderali Lars L, Sander Leif-Erik LE, Drosten Christian C, Laudi Sven S, Eils Roland R, Conrad Christian C, Landmesser Ulf U, Lehmann Irina ICOVID19, Disease, Coronavirus Disease 19, β-CoV, beta-CoV, High Blood Pressures, COVID-19, 2019-nCoV Infections., SARS-CoV-2, Virus Infection, COVID-19 Virus Diseases, 2019 novel coronavirus, 2019 Novel Coronavirus Disease, SARS-CoV-2 Infections, 2019 nCoV Infection, High blood pressure, COVID 19 Virus Infection, Client, Virus Disease, 2019 nCoV Disease, COVID-19 Virus Disease, 2019-nCoV Infection, tracheobronchial tree segment, Blood Pressures, 2019-nCoV Disease, SARS CoV 2 Infection, Infection, Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Coronavirus, COVID-19 Virus Infections, β-coronavirus, 2019-nCoV, COVID 19 Pandemic, Blood Pressure, HTN, β-CoVs, betacoronavirus, Disease 2019, airways, Pandemic, COVID-19 Virus Infection, Coronavirus Disease 2019, segment of tracheobronchial tree, severe acute respiratory syndrome coronavirus 2, Coronavirus Disease-19, COVID-19 Pandemics, SARS-CoV-2 Infection, COVID-19 Pandemic, beta-CoVs, respiratory conducting tube, SARS-coronavirus 2, Hypertension, High, COVID-19 Virus, airway, Patient, Clients, 2019 Novel Coronavirus Infection, 2019-nCoV Diseases, COVID 19 Virus Disease, SARS Coronavirus 2 Infection, COVID 19, High Blood Pressure, hypertensionOther diseases of pericardium (disorder), Cardiovascular disease, SCYAR1, Other pericardial disease NOS (disorder), Cardiovascular disorder, PAPILLARY MUSCLE DIS NEC, Virus Infection, LD78alpha, Risk Factor Score, carboxycathepsin inhibitors, Antiviral, Antiviral Agent, MIP-1alpha, Polymorphonuclear, dmTAF[[II]]230, unspecified, Risk Factors, Disease of cardiovascular system (disorder), T22F8_160, Other heart disease NOS, Chemokine, GRP8, LE Cell, Correlates, Progression, Neutrophil Band Cells, treatment, Cardiovascular Diseases, Kininase II Inhibitor, TFIID TAF250, cel, AT744.1, [X]Other forms of heart disease (disorder), tetrachloridocarbon, Coronavirus Disease 2019, Other ill-defined heart disease (disorder), PMNC, X, beta-CoVs, circulatory system disease, HC21, Social, ACE, Angiotensin Receptor, Disorder of cardiovascular system, Health Correlates, Kininase II Inhibitors, COVID 19 Virus Disease, 2019-nCoV Infections, Circulatory system disease NOS (disorder), dTAF[[II]]230, β-CoV, Kininase II Antagonists, Angiotensin I Converting Enzyme Inhibitors, Tetrachlorkohlenstoff, SARS-CoV-2, TAF200, PMN cell, CKR1, 2019 nCoV Infection, COVID 19 Virus Infection, High blood pressure, disease of subdivision of hemolymphoid system, Neutrophil Band Cell, PDH inhibitors, Angiotensin II Receptor, CC-CKR-1, Angiotensin I-Converting Enzyme Inhibitor, TU15B, Chemokine Receptors, CARDIOVASC DIS, ACE inhibitors, Monocyte-Derived Macrophages, GLYCINE-RICH PROTEIN 8, HTN, CD191, Social Risk Factors, ACE Inhibitor, Pandemic, Antagonists, DCP inhibitor, Chemokine Receptor, Disorder of the circulatory system, [X]Other ill-defined heart diseases (disorder), Angiotensin II, LAG1, NEUTSGNE, respiratory conducting tube, white blood cell, endothelial cell peptidyl dipeptidase inhibitor, Taf250, ILL-DEFINED HRT DIS NEC, Polymorphonuclear Leukocytes, 2019-nCoV Diseases, Antivirals, Disease affecting entire cardiovascular system, peptidyl dipeptidase A inhibitor, Macrophage inflammatory protein 1-alpha receptor, hypertension, Angiotensin-Converting Enzyme Inhibitor, TAF230, PDH inhibitor, peptidyldipeptide hydrolase inhibitor, EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitors, Band Cell, Cardiovascular system disease, COVID-19, Other diseases of pericardium, Other disorders of papillary muscle, Adverse, Angiotensin III Receptor, and RNA binding 1, unspecified (disorder), Agent, Disorder of cardiovascular system (disorder), Cardiac, EC 3.4.15.1 inhibitors, Severe Acute Respiratory Syndrome Coronavirus 2 Infection, β-coronavirus, endothelial cell peptidyl dipeptidase inhibitors, Other ill-defined heart disease NOS (disorder), 2019-nCoV, Unspecified circulatory system disorder, Risk Factor, Blood Pressure, β-CoVs, dTAF[[II]]250, Clinical, C-C CKR-1, cell, VMD2, COVID-19 Virus Infection, study., severe acute respiratory syndrome coronavirus 2, Other forms of heart disease, peptidyl-dipeptidase A inhibitor, Bone Marrow-Derived Macrophage, MIP-1alpha-R, BMD, SARS-CoV-2 Infection, Other specified pericardial disease NOS, Population at Risk, cardiovascular disease, Bone Marrow-Derived, dTAF250, COVID-19 Virus, Neutrophils, Clinical Course, Kininase, SCYA3, ATGRP8, SCYA2, SCYA4, MIP-1-beta, LE, Scya3, Scya4, OTHER SEQUELAE OF MI NEC, Enzyme Inhibitor, RP50, Coronavirus Disease 19, Polymorphonuclear Neutrophils, beta-CoV, Leukocytes, peptidyl dipeptidase I inhibitor, Factor, BG:DS00004.13, SARS-CoV-2 Infections, Disease affecting entire cardiovascular system (disorder), peptidase P inhibitors, Cell, Polymorphonuclear Leukocyte, dTAF230, COVID-19 Virus Disease, Monocyte-Derived, Cmkbr1, Cytokine, tracheobronchial tree segment, G-26, ACE Inhibitors, TAF[[II]]250/230, CCl4, Other ill-defined heart disease NOS, epitheliocyte, Tetra, angiotensin I-converting enzyme inhibitors, ACE inhibitor, Angiotensin-Converting, EC 3.4.15.1 inhibitor, carboxycathepsin inhibitor, Macrophage, Other specified diseases of pericardium, Taf[[II]]250, Enzyme Inhibitors, Cardiovascular, leucocyte, betacoronavirus, kininase II inhibitors, [X]Other ill-defined heart diseases, Macrophages, increased number, Angiotensin-Converting Enzyme, GR-RBP8, [X]Other forms of heart disease, Other sequelae of myocardial infarction, COVID-19 Pandemics, COVID-19 Pandemic, High, CVS disease, T24D18_5, IRX4, Bone Marrow-Derived Macrophages, Receptor, peptidase P inhibitor, BEST, COVID 19, dipeptidase inhibitors, Angiotensin III, T22F8.160, Angiotensin I-Converting Enzyme Inhibitors, peptidyl-dipeptidase A (EC 3.4.15.1) inhibitors, Other heart disease NOS (disorder), 2019 novel coronavirus, Cardiac Event, Virus Disease, [X]Other specified diseases of pericardium (disorder), 2019 nCoV Disease, ACT2, Enzyme Antagonists, ATCRR1, 2019-nCoV Disease, Monocyte-Derived Macrophage, CVD, ARB, Angiotensin I Converting Enzyme Inhibitor, Inhibitors, peptidyl dipeptide hydrolase inhibitors, COVID 19 Pandemic, MIP-1-alpha, increased, peptidyl-dipeptidase A (EC 3.4.15.1) inhibitor, MIP1-alpha, Other diseases of endocardium, Act-2, Coronavirus Disease-19, LD78ALPHA, CCR1, dipeptide hydrolase inhibitor, Angiotensin Converting Enzyme Inhibitors, disease management, Exacerbation, Therapies, Mip1-b, glycine-rich RNA-binding protein 8, Event, dipeptidyl carboxypeptidase inhibitors, Therapy, bestrophinopathy, dipeptidyl carboxypeptidase I inhibitors, High Blood Pressures, Disease Exacerbation, dipeptide hydrolase inhibitors, macrophage inflammatory protein 1-beta, Disorder of circulatory system, 2019 Novel Coronavirus Disease, ATCCR1, TAFII-250, TAF250/230, angiotensin-converting enzyme inhibitors, PAS14, TAFII250, LE Cells, epithelial, Adverse Cardiac Event, Score, peptidyldipeptide hydrolase inhibitors, Coronavirus, NOS, Other pericardial disease NOS, COVID-19 Virus Infections, CIRCULATORY DISEASE NOS, autosomal recessive, MIP1aR, Polymorphonuclear Neutrophil, Factors, RANTES-R, peptidyl dipeptidase-4 inhibitors, Risk, cold, peptidyl-dipeptidase A inhibitors, Adverse Cardiac Events, Mip-1a-R, CCR-1, CG17603, Kininase II, TAF[[II]], LAG-1, Treatments, cinnamoyl coa reductase 1, Hypertension, MIP1B1, Social Risk, Health, airway, Angiotensin Converting Enzyme, Agents, Patient, SR3-5, 2019 Novel Coronavirus Infection, Inhibitor, accessory, polymorphonuclear cell, Cardiovascular Disorders, COVID19, ASCVD, d230, MIP-1a, peptidyl dipeptidase I inhibitors, Monocyte Derived Macrophages, DCP inhibitors, Other heart disease (disorder), COVID-19 Virus Diseases, dTAFII250, circadian rhythm, peptidyl dipeptide hydrolase inhibitor, EfW1, supernumerary, G0S19-1, Antiviral Drug, [X]Cardiovascular disease, CAT1, dmTAF1, Blood Pressures, Taf230, SARS CoV 2 Infection, Clinical Progression, dipeptidyl carboxypeptidase inhibitor, angiotensin-converting enzyme inhibitor, kininase II inhibitor, dipeptidyl carboxypeptidase I inhibitor, MIP1B, MIP1A, TAF250, Drugs, Segmented/Neutrophils, Taf200, Other diseases of endocardium (disorder), Populations at Risk, HAF3, [X]Other specified diseases of pericardium, angiotensin I-converting enzyme inhibitor, airways, peptidyl dipeptidase-4 inhibitor, Other heart disease, Risk Score, segment of tracheobronchial tree, Taf1p, HM145, dipeptidase inhibitor, Angiotensin-Converting Enzyme Antagonists, Angiotensin Converting Enzyme Inhibitor, Clients, MIP1-(a), Social Risk Factor, Disease of cardiovascular system, TAF, SARS Coronavirus 2 Infection, Circulatory system disease NOS, Neutrophil, Tetrachlormethan, High Blood Pressure, AI323804, Disease, Other ill-defined heart diseases, TAF[[II]]250, Leukocyte, LD78 receptor, immune cell, not elsewhere classified, CINNAMOYL COA REDUCTASE, l(3)84Ab, CRINKLY4 related 1, CMKBR1, Kohlenstofftetrachlorid, Monocyte Derived, Antiviral Drugs, Risk Factor Scores, Client, Other ill-defined heart disease, lymphocyte activation gene 1 protein, peptidyl dipeptidase A inhibitors, 2019-nCoV Infection, Angiotensin Receptors, Cardiac Events, p230, Infection, Angiotensin Converting Enzyme Antagonists, TFIID, peptidyl-dipeptide hydrolase inhibitor, Other forms of heart disease (disorder), PERICARDIAL DISEASE NEC, IRREGULAR XYLEM 4, Carbon tetrachloride, Disease 2019, TAF[[II]]230, distinct, peptidyl-dipeptide hydrolase inhibitors, Bone Marrow Derived Macrophages, GLC2, TAF[II]250, SPBC365.17, CKR-1, SARS-coronavirus 2, Risk Scores, Cardiovascular Disease, Drug, present in greater numbers in organism, Other specified pericardial disease NOS (disorder), MIP-1B, DmelCG17603, Therapeutic, Mip1a, Mip1b, Treatment, Major Adverse Cardiac Events, II Inhibitor, Angiotensin, T24D18.5, Intrinsic, TAF1COVID19, Disease, Coronavirus Disease 19, β-CoV, beta-CoV, High Blood Pressures, COVID-19, 2019-nCoV Infections., SARS-CoV-2, Virus Infection, COVID-19 Virus Diseases, 2019 novel coronavirus, 2019 Novel Coronavirus Disease, SARS-CoV-2 Infections, 2019 nCoV Infection, High blood pressure, COVID 19 Virus Infection, Client, Virus Disease, 2019 nCoV Disease, COVID-19 Virus Disease, 2019-nCoV Infection, tracheobronchial tree segment, Blood Pressures, 2019-nCoV Disease, SARS CoV 2 Infection, Infection, Severe Acute Respiratory Syndrome Coronavirus 2 Infection, Coronavirus, COVID-19 Virus Infections, β-coronavirus, 2019-nCoV, COVID 19 Pandemic, Blood Pressure, HTN, β-CoVs, betacoronavirus, Disease 2019, airways, Pandemic, COVID-19 Virus Infection, Coronavirus Disease 2019, segment of tracheobronchial tree, severe acute respiratory syndrome coronavirus 2, Coronavirus Disease-19, COVID-19 Pandemics, SARS-CoV-2 Infection, COVID-19 Pandemic, beta-CoVs, respiratory conducting tube, SARS-coronavirus 2, Hypertension, High, COVID-19 Virus, airway, Patient, Clients, 2019 Novel Coronavirus Infection, 2019-nCoV Diseases, COVID 19 Virus Disease, SARS Coronavirus 2 Infection, COVID 19, High Blood Pressure, hypertensionOther diseases of pericardium (disorder), Cardiovascular disease, SCYAR1, Other pericardial disease NOS (disorder), Cardiovascular disorder, PAPILLARY MUSCLE DIS NEC, Virus Infection, LD78alpha, Risk Factor Score, carboxycathepsin inhibitors, Antiviral, Antiviral Agent, MIP-1alpha, Polymorphonuclear, dmTAF[[II]]230, unspecified, Risk Factors, Disease of cardiovascular system (disorder), T22F8_160, Other heart disease NOS, Chemokine, GRP8, LE Cell, Correlates, Progression, Neutrophil Band Cells, treatment, Cardiovascular Diseases, Kininase II Inhibitor, TFIID TAF250, cel, AT744.1, [X]Other forms of heart disease (disorder), tetrachloridocarbon, Coronavirus Disease 2019, Other ill-defined heart disease (disorder), PMNC, X, beta-CoVs, circulatory system disease, HC21, Social, ACE, Angiotensin Receptor, Disorder of cardiovascular system, Health Correlates, Kininase II Inhibitors, COVID 19 Virus Disease, 2019-nCoV Infections, Circulatory system disease NOS (disorder), dTAF[[II]]230, β-CoV, Kininase II Antagonists, Angiotensin I Converting Enzyme Inhibitors, Tetrachlorkohlenstoff, SARS-CoV-2, TAF200, PMN cell, CKR1, 2019 nCoV Infection, COVID 19 Virus Infection, High blood pressure, disease of subdivision of hemolymphoid system, Neutrophil Band Cell, PDH inhibitors, Angiotensin II Receptor, CC-CKR-1, Angiotensin I-Converting Enzyme Inhibitor, TU15B, Chemokine Receptors, CARDIOVASC DIS, ACE inhibitors, Monocyte-Derived Macrophages, GLYCINE-RICH PROTEIN 8, HTN, CD191, Social Risk Factors, ACE Inhibitor, Pandemic, Antagonists, DCP inhibitor, Chemokine Receptor, Disorder of the circulatory system, [X]Other ill-defined heart diseases (disorder), Angiotensin II, LAG1, NEUTSGNE, respiratory conducting tube, white blood cell, endothelial cell peptidyl dipeptidase inhibitor, Taf250, ILL-DEFINED HRT DIS NEC, Polymorphonuclear Leukocytes, 2019-nCoV Diseases, Antivirals, Disease affecting entire cardiovascular system, peptidyl dipeptidase A inhibitor, Macrophage inflammatory protein 1-alpha receptor, hypertension, Angiotensin-Converting Enzyme Inhibitor, TAF230, PDH inhibitor, peptidyldipeptide hydrolase inhibitor, EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitors, Band Cell, Cardiovascular system disease, COVID-19, Other diseases of pericardium, Other disorders of papillary muscle, Adverse, Angiotensin III Receptor, and RNA binding 1, unspecified (disorder), Agent, Disorder of cardiovascular system (disorder), Cardiac, EC 3.4.15.1 inhibitors, Severe Acute Respiratory Syndrome Coronavirus 2 Infection, β-coronavirus, endothelial cell peptidyl dipeptidase inhibitors, Other ill-defined heart disease NOS (disorder), 2019-nCoV, Unspecified circulatory system disorder, Risk Factor, Blood Pressure, β-CoVs, dTAF[[II]]250, Clinical, C-C CKR-1, cell, VMD2, COVID-19 Virus Infection, study., severe acute respiratory syndrome coronavirus 2, Other forms of heart disease, peptidyl-dipeptidase A inhibitor, Bone Marrow-Derived Macrophage, MIP-1alpha-R, BMD, SARS-CoV-2 Infection, Other specified pericardial disease NOS, Population at Risk, cardiovascular disease, Bone Marrow-Derived, dTAF250, COVID-19 Virus, Neutrophils, Clinical Course, Kininase, SCYA3, ATGRP8, SCYA2, SCYA4, MIP-1-beta, LE, Scya3, Scya4, OTHER SEQUELAE OF MI NEC, Enzyme Inhibitor, RP50, Coronavirus Disease 19, Polymorphonuclear Neutrophils, beta-CoV, Leukocytes, peptidyl dipeptidase I inhibitor, Factor, BG:DS00004.13, SARS-CoV-2 Infections, Disease affecting entire cardiovascular system (disorder), peptidase P inhibitors, Cell, Polymorphonuclear Leukocyte, dTAF230, COVID-19 Virus Disease, Monocyte-Derived, Cmkbr1, Cytokine, tracheobronchial tree segment, G-26, ACE Inhibitors, TAF[[II]]250/230, CCl4, Other ill-defined heart disease NOS, epitheliocyte, Tetra, angiotensin I-converting enzyme inhibitors, ACE inhibitor, Angiotensin-Converting, EC 3.4.15.1 inhibitor, carboxycathepsin inhibitor, Macrophage, Other specified diseases of pericardium, Taf[[II]]250, Enzyme Inhibitors, Cardiovascular, leucocyte, betacoronavirus, kininase II inhibitors, [X]Other ill-defined heart diseases, Macrophages, increased number, Angiotensin-Converting Enzyme, GR-RBP8, [X]Other forms of heart disease, Other sequelae of myocardial infarction, COVID-19 Pandemics, COVID-19 Pandemic, High, CVS disease, T24D18_5, IRX4, Bone Marrow-Derived Macrophages, Receptor, peptidase P inhibitor, BEST, COVID 19, dipeptidase inhibitors, Angiotensin III, T22F8.160, Angiotensin I-Converting Enzyme Inhibitors, peptidyl-dipeptidase A (EC 3.4.15.1) inhibitors, Other heart disease NOS (disorder), 2019 novel coronavirus, Cardiac Event, Virus Disease, [X]Other specified diseases of pericardium (disorder), 2019 nCoV Disease, ACT2, Enzyme Antagonists, ATCRR1, 2019-nCoV Disease, Monocyte-Derived Macrophage, CVD, ARB, Angiotensin I Converting Enzyme Inhibitor, Inhibitors, peptidyl dipeptide hydrolase inhibitors, COVID 19 Pandemic, MIP-1-alpha, increased, peptidyl-dipeptidase A (EC 3.4.15.1) inhibitor, MIP1-alpha, Other diseases of endocardium, Act-2, Coronavirus Disease-19, LD78ALPHA, CCR1, dipeptide hydrolase inhibitor, Angiotensin Converting Enzyme Inhibitors, disease management, Exacerbation, Therapies, Mip1-b, glycine-rich RNA-binding protein 8, Event, dipeptidyl carboxypeptidase inhibitors, Therapy, bestrophinopathy, dipeptidyl carboxypeptidase I inhibitors, High Blood Pressures, Disease Exacerbation, dipeptide hydrolase inhibitors, macrophage inflammatory protein 1-beta, Disorder of circulatory system, 2019 Novel Coronavirus Disease, ATCCR1, TAFII-250, TAF250/230, angiotensin-converting enzyme inhibitors, PAS14, TAFII250, LE Cells, epithelial, Adverse Cardiac Event, Score, peptidyldipeptide hydrolase inhibitors, Coronavirus, NOS, Other pericardial disease NOS, COVID-19 Virus Infections, CIRCULATORY DISEASE NOS, autosomal recessive, MIP1aR, Polymorphonuclear Neutrophil, Factors, RANTES-R, peptidyl dipeptidase-4 inhibitors, Risk, cold, peptidyl-dipeptidase A inhibitors, Adverse Cardiac Events, Mip-1a-R, CCR-1, CG17603, Kininase II, TAF[[II]], LAG-1, Treatments, cinnamoyl coa reductase 1, Hypertension, MIP1B1, Social Risk, Health, airway, Angiotensin Converting Enzyme, Agents, Patient, SR3-5, 2019 Novel Coronavirus Infection, Inhibitor, accessory, polymorphonuclear cell, Cardiovascular Disorders, COVID19, ASCVD, d230, MIP-1a, peptidyl dipeptidase I inhibitors, Monocyte Derived Macrophages, DCP inhibitors, Other heart disease (disorder), COVID-19 Virus Diseases, dTAFII250, circadian rhythm, peptidyl dipeptide hydrolase inhibitor, EfW1, supernumerary, G0S19-1, Antiviral Drug, [X]Cardiovascular disease, CAT1, dmTAF1, Blood Pressures, Taf230, SARS CoV 2 Infection, Clinical Progression, dipeptidyl carboxypeptidase inhibitor, angiotensin-converting enzyme inhibitor, kininase II inhibitor, dipeptidyl carboxypeptidase I inhibitor, MIP1B, MIP1A, TAF250, Drugs, Segmented/Neutrophils, Taf200, Other diseases of endocardium (disorder), Populations at Risk, HAF3, [X]Other specified diseases of pericardium, angiotensin I-converting enzyme inhibitor, airways, peptidyl dipeptidase-4 inhibitor, Other heart disease, Risk Score, segment of tracheobronchial tree, Taf1p, HM145, dipeptidase inhibitor, Angiotensin-Converting Enzyme Antagonists, Angiotensin Converting Enzyme Inhibitor, Clients, MIP1-(a), Social Risk Factor, Disease of cardiovascular system, TAF, SARS Coronavirus 2 Infection, Circulatory system disease NOS, Neutrophil, Tetrachlormethan, High Blood Pressure, AI323804, Disease, Other ill-defined heart diseases, TAF[[II]]250, Leukocyte, LD78 receptor, immune cell, not elsewhere classified, CINNAMOYL COA REDUCTASE, l(3)84Ab, CRINKLY4 related 1, CMKBR1, Kohlenstofftetrachlorid, Monocyte Derived, Antiviral Drugs, Risk Factor Scores, Client, Other ill-defined heart disease, lymphocyte activation gene 1 protein, peptidyl dipeptidase A inhibitors, 2019-nCoV Infection, Angiotensin Receptors, Cardiac Events, p230, Infection, Angiotensin Converting Enzyme Antagonists, TFIID, peptidyl-dipeptide hydrolase inhibitor, Other forms of heart disease (disorder), PERICARDIAL DISEASE NEC, IRREGULAR XYLEM 4, Carbon tetrachloride, Disease 2019, TAF[[II]]230, distinct, peptidyl-dipeptide hydrolase inhibitors, Bone Marrow Derived Macrophages, GLC2, TAF[II]250, SPBC365.17, CKR-1, SARS-coronavirus 2, Risk Scores, Cardiovascular Disease, Drug, present in greater numbers in organism, Other specified pericardial disease NOS (disorder), MIP-1B, DmelCG17603, Therapeutic, Mip1a, Mip1b, Treatment, Major Adverse Cardiac Events, II Inhibitor, Angiotensin, T24D18.5, Intrinsic, TAF1falseHypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19In coronavirus disease 2019 (COVID-19), hypertension and cardiovascular diseases are major risk factors for critical disease progression. However, the underlying causes and the effects of the main anti-hypertensive therapies-angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs)-remain unclear. Combining clinical data (n = 144) and single-cell sequencing data of airway samples (n = 48) with in vitro experiments, we observed a distinct inflammatory predisposition of immune cells in patients with hypertension that correlated with critical COVID-19 progression. ACEI treatment was associated with dampened COVID-19-related hyperinflammation and with increased cell intrinsic antiviral responses, whereas ARB treatment related to enhanced epithelial-immune cell interactions. Macrophages and neutrophils of patients with hypertension, in particular under ARB treatment, exhibited higher expression of the pro-inflammatory cytokines CCL3 and CCL4 and the chemokine receptor CCR1. Although the limited size of our cohort does not allow us to establish clinical efficacy, our data suggest that the clinical benefits of ACEI treatment in patients with COVID-19 who have hypertension warrant further investigation.2021-02-16 08:02:27EGAS00001004772960633361824MONDO_0100096EGAD00001006828EGAC00001001627